Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 11, 2012, Pages

  Cox, Georgina R ^a   Fisher, Caroline A ^a,b   De Silva, Stefanie ^a   Phelan, Mark ^a   Akinwale, Olaoluwa P ^c   Simmons, Magenta B ^a   Hetrick, Sarah E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^c NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ACCEPTANCE AND COMMITMENT THERAPY; ADOLESCENT; BECK DEPRESSION INVENTORY; CHILD; CHILD PSYCHIATRY; COGNITIVE BEHAVIORAL THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG SAFETY; DYSTHYMIA; HAMILTON DEPRESSION RATING SCALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR DEPRESSION; MORBIDITY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REVIEW; SIDE EFFECT; SOCIAL INTERACTION; SYSTEMATIC REVIEW; THERAPY EFFECT; TIME TO TREATMENT; TREATMENT OUTCOME; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSIVE DISORDER; HUMANS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84872197151     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007504.pub2     Document Type: Review

References (127)

1. Cheung A, Kusumakar V, Kutcher S, Dubo E, Garland J, Weiss M, et al.Maintenance study for adolescent depression. Journal of Child and Adolescent Psychopharmacology 2008;4:389-94.
2. Clarke GN, Rohde P, Lewinsohn PM, Hops H, Seeley JR. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. Journal of the American Academy of Child & Adolescent Psychiatry 1999; Vol. 38, issue 3:272-9.
3. Emslie GJ. Depression in children and adolescents [conference abstract]. 9th Congress of the Association of European Psychiatrists. Copenhagen, Denmark. Sept 20-24, 1998.
4. Emslie GJ, Heiligenstein JH, Hoog SL, Ernest DE, VanHooy B, Brown E, et al.Fluoxetine for maintenance of recovery from depression in children and adolescents: a placebo-controlled, randomized clinical trial [Abstract No. NR736]. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, LA. Arlington, VA: American Psychiatric Association, 2001.
5. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depression and Anxiety 1998;7:32-9.
6. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T. A double-blind placebo controlled trial of fluoxetine in depressed children and adolescents [conference abstract]. Sixth World Congress of Biological Psychiatry, Nice, France. June 22-27, 1997.
7. Emslie GJ, Rush R, Weinberg WA, Kowatch WA, Hughes CW, Carmody T, et al.A double blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 1997;54(11):1031-7.
8. Hughes CW, Emslie G, Kowatch R, Weinberg W, Rintelmann J, Rush AJ. Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology 2000;23(5):591-4.
9. Kowatch RA, Carmody TJ, Emslie GJ, Rintelmann JW, Hughes CW, Rush AJ. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. Journal of Affective Disorders 1999;54(3):269-76.
10. Emslie GJ, Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, McCracken JT, et al.Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double blind, placebo-controlled study. Journal of the American Academy of Child & Adolescent Psychiatry 2004; Vol. 43, issue 11:1397-405.
11. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al.Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry 2002;41(10):1205-15.
12. Emslie GJ, Kennard BD, Mayes TL, Nightingale-Teresi J, Carmody T, Hughes CW, et al.Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. American Journal of Psychiatry 2008;165:459-67.
13. Kennard BD, Emslie GJ, Mayes TL, Nightingale-Teresi J, Nakonezny PA, Hughes JL, et al.Cognitive-behavioral therapy to prevent relapse in paediatric responders to pharmacotherapy for major depressive disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2008;47(12):1395-404.
14. Birmaher B, Brent DA, Kolko D, Baugher M, Bridge J, Holder D, et al.Clinical outcomes after short-term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry 2000;57:29-36.
15. Brent DA, Birmaher B, Kolko D, Baugher M, Bridge J. Subsyndromal depression in adolescents after a brief psychotherapy trial: course and outcome. Journal of Affective Disorders 2001;63(1-3):51-8.
16. Brent DA, Holder D, Kolko D, Birmaher B, Baugher M, Roth C, et al.A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Archives of General Psychiatry 1997;54(9):877-85.
17. Brent DA, Kolko DJ, Birmaher B, Baugher M, Bridge J. A clinical trial for adolescent depression: predictors of additional treatment in the acute and follow-up phases of the trial. Journal of the American Academy of Child & Adolescent Psychiatry 1999;38(3):253-70.
18. Kolko DJ, Brent DA, Baugher M, Bridge J, Birmaher B. Cognitive and family therapies for adolescent depression: treatment specificity, mediation, and moderation. Journal of Consulting and Clinical Psychology 2000;68(4):603-14.
19. Renaud J, Brent DA, Baugher M, Birmaher B, Kolko D J, Bridge J. Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up. Journal of the American Academy of Child & Adolescent Psychiatry 1998;37(11):1184-90.
20. Weersing VR, Brent DA. Cognitive-behavioral therapy for adolescent depression: comparative efficacy, mediation, moderation and effectiveness. Evidence-based psychotherapies for children and adolescents. New York, NY: Guilford Press, 2003:135-47.
21. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, et al.Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. American Academy of Child and Adolescent Psychiatry 2009;48(7):711-20.
22. Kennard BD, Silva SG, Mayes TL, Hughes JL, Kratochvil CJ, Emslie GJ, et al.Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. American Journal of Psychiatry 2009;166(3):337-44.
23. Kennard BD, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, et al.Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. Journal of the American Academy of Child & Adolescent Psychiatry 2009;48(2):186-95.
24. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al.The Treatment for Adolescents with Depression Study (TADS): demographic and clinical characteristics. Journal of the American Academy of Child & Adolescent Psychiatry 2005;44(1):28-40.
25. March J, Silva S, Vitiello B. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. Journal of the American Academy of Child & Adolescent Psychiatry 2006;45(12):1393-403.
26. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al.The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Archives of General Psychiatry 2007;64(10):1132-43.
27. Rohde P, Silva SG, Tonev ST, Kennard BD, Vitiello B, Kratochvil CJ, et al.Achievement and maintenance of sustained response during the Treatment for Adolescents with Depression Study continuation and maintenance therapy. Archives of General Psychiatry 2008;65(4):447-55.
28. Simons AD, Rohde P, Kennard BD, Robins M. Relapse and recurrence prevention in the Treatment for Adolescents with Depression Study. Cognitive and Behavioral Practice 2005;12(2):240-51.
29. Treatment for Adolescents with Depression Study Team. The Treatment for Adolescents with Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. American Journal of Psychiatry 2009;166(10):1141-9.
30. Emslie GJ, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD, et al.Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. American Journal of Psychiatry 2010;167(7):782-91.
31. Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, et al.Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. Journal of Clinical Psychiatry 2011;72(3):388-96.
32. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al.Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335(7611):142.
33. Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al.A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technology Assessment 2008;12(14):iii-iv, ix-60.
34. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, Balach L, et al.Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. Journal of the American Academy of Child & Adolescent Psychiatry 1998;37(5):527-35.
35. Birmaher B, Brent DA, Kolko D, Baugher M, Bridge J, Holder D, et al.Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry 2000;57(1):29-36.
36. Eli Lilly. Fluoxetine: fluoxetine versus placebo in adolescent depressed patients [Trial 236]. Eli Lilly - Clinical Study Register (http://www.lillytrials.com) 1986.
37. Eli Lilly. Fluoxetine versus placebo in the acute treatment of major depressive disorder in children and adolescents [Trial 375]. Eli Lilly - Clinical Study Register (http://www.lillytrials.com) 1995.
38. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris A. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. Journal of the American Academy of Child & Adolescent Psychiatry 2009;48(7):721-9.
39. Forest Laboratories. A double-blind, fixed-dose extension study of escitalopram in pediatric patients with major depressive disorder [SCT-MD-32/32A]. Forest Laboratories - Clinical Study Register (http://www.forestclinicaltrials.com) 2007.
40. Franchini L, Bongiorno F, Spagnolo C, Florita M, Santoro A, Dotoli D, et al.Psychoeducational group intervention in addition to antidepressant therapy as relapse preventive strategy in unipolar patients. Clinical Neuropsychiatry 2006; Vol. 3, issue 4:282-5.
41. Glaxo Smith Kline . A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - acute phase (29060/329). GSK - Clinical Study Register (http://www.gsk-clinicalstudyregister.com) 1997.
42. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al.Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry 2001;40(7):762-72.
43. GlaxoSmithKline . A randomized, multi-center, 8-week, double-blind, placebo-controlled, flexible-dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder (MDD). GSK - Clinical Study Register (http://www.gsk-clinicalstudyregister.com) 2001.
44. Jacobs RH, Silva SG, Reinecke MA, Curry JF, Ginsburg GS, Kratochvil CJ, et al.Dysfunctional attitudes scale perfectionism: a predictor and partial mediator of acute treatment outcome among clinically depressed adolescents. Journal of Clinical Child & Adolescent Psychology 2009;38(6):803-13.
45. Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, et al.Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). Journal of the American Academy of Child & Adolescent Psychiatry 2006;45(12):1404-11.
46. Kratochvil C, Emslie G, Silva S, McNulty S, Walkup J, Curry J, et al.Acute time to response in the Treatment for Adolescents with Depression Study (TADS). Journal of the American Academy of Child & Adolescent Psychiatry 2006;45(12):1412-8.
47. Lewis CC, Simons AD, Silva SG, Rohde P, Small DM, Murakami JL, et al.The role of readiness to change in response to treatment of adolescent depression. Journal of Consulting and Clinical Psychology 2009;77(3):422-8.
48. Oleichik IV, Artiouch VV. The treatment of cognitive symptoms of adolescent endogenous depressive disorders. 11th European College of Neuropsychopharmacology Congress, Paris, France. 31st October - 4th November 1998.
49. Goodyer IM, Tsancheva S, Byford S, Dubicka B, Hill J, Kelvin R, et al.Improving mood with psychoanalytic and cognitive therapies (IMPACT): a pragmatic effectiveness superiority trial to investigate whether specialised psychological treatment reduces the risk for relapse in adolescents with moderate to severe unipolar depression: study protocol for a randomised controlled trial. Trials 2011;12:175.
50. Emslie GJ. Pediatric MDD: sequential treatment with fluoxetine and relapse prevention. ClinicalTrials.gov (http://www.clinicaltrials.gov) 2008; Vol. http://clinicaltrials.gov/show/NCT00612313 (accessed 23 November 2011).
51. American Academy of Child, Adolescent Psychiatry (AACAP). Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child & Adolescent Psychiatry 2007;46(11):1503-26.
52. Allen NB, Hetrick SE, Simmons JG, Hickie IB. Early intervention in depressive disorders in young people: the opportunity and the (lack of) evidence. Medical Journal of Australia 2007;187(7):s15-7.
53. Alvarez-Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophrenia Bulletin 2011;37(3):619-30.
54. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
55. Beck AT, Ward CH, Mendelssohn MJ, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
56. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychological Bulletin 1988;104(1):84-96.
57. Berndt ER, Koran LM, Finkelstein SN, Gelenberg AJ, Kornstein SG, Miller IM, et al.Lost human capital from early-onset chronic depression. American Journal Psychiatry 2000;157(6):940-7.
58. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE. Childhood and adolescent depression: a review of the past 10 years: part 1. Journal of the American Academy of Child & Adolescent Psychiatry 1996;35(11):1427-39.
59. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al.Clinical response and risk for reported suicidal ideation and suicide attempts in paediatric antidepressant treatment a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683-96.
60. Zuckerbrot RA, Cheung AH, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, et al.Guidelines for adolescent depression in primary care (GLAD-PC): II treatment and ongoing management. Pediatrics 2007;120:e1313-26.
61. Churchill R, Moore THM, Davies P, Caldwell D, Jones H, Lewis G, et al.Mindfulness-based 'third wave' cognitive and behavioural therapies versus treatment as usual for depression. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD008705]
62. Clarke GN, Lewinsohn PM, Hops H, Seeley JR. Instructors Manual for the Adolescent Coping With Depression Course. Eugene, OR: Castalia Press, 1990.
63. Clarke G, Debar L, Lynch F, Powell J, Gale J, O'Connor E, et al.A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. Journal of the American Academy of Child & Adolescent Psychiatry 2005;44:888-98.
64. Costello JE, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression?. Journal of Child Psychology and Psychiatry 2006;47(12):1263-71.
65. Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, et al.Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database of Systematic Reviews 2012.
66. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al.The impact of treatment-resistant depression on health care utilization and costs. Journal of Clinical Psychiatry 2002;63(11):963-71.
67. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
68. Dobson KS, Dimidjian S, Kohlenberg RJ, Rizvi SL, Dunner DL, Jacobson NS, et al.Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. Journal of Consulting and Clinical Psychology 2008;76(3):468-77.
69. Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA. Six-year outcome for cognitive behavioral treatment of residual symptoms for major depression. American Journal of Psychiatry 1998;155:1443-5.
70. Fisher CA, Hetrick SE, Rushford N. Family therapy for anorexia nervosa. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD004780.pub2]
71. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al.Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 1991;48:851-5.
72. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361(9358):653-61.
73. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al.Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335(7611):142.
74. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960;23:56-62.
75. Harrington R, Fudge H, Rutter M, Pickles A, Hill J. Adult outcomes of childhood and adolescent depression. 1. Psychiatric status. Archives of General Psychiatry 1990;47(5):465-73.
76. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002317]
77. Healy D. The Anti-Depressant Era. Massachusetts: Harvard University Press, 1997.
78. Hensley PL, Nadiga D, Uhlenhuth EH. Long-term effectiveness of cognitive therapy in major depressive disorder. Depression and Anxiety 2004;20(1):1-7.
79. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004851.pub2]
80. Hetrick SE, Parker AG, Purcell R, Hickie I, Yung AR, McGorry PD. Early identification and intervention in depressive disorders: toward a clinical staging model. Journal of Psychotherapy and Psychosomatics 2008;77(5):263-70.
81. Hetrick SE, McKenzie JE, Cox GR, Simmons M, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2012.
82. Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
83. Higgins JPT, Altman DG, On behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
84. Hofmann SG, Asmundson GJG. Acceptance and mindfulness-based therapy: new wave or old hat?. Clinical Psychology Review 2008;28(1):1-16.
85. Jaffee SR, Moffitt TE, Caspi A, Fombonne E, Poulton R, Martin J. Differences in early childhood risk factors for juvenile-onset and adult-onset depression. Archives of General Psychiatry 2002;59(3):215-22.
86. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Archives of General Psychiatry 2001;58:381-8.
87. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcomes of episodes of major depression: clinical and public health significance. JAMA 1984;252:788-92.
88. Keller MB, Ruwe FKL, Janssens CJJG, Sitsen JMA, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. Journal of Clinical Pharmacology 2005;25(1):79-84.
89. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. American Journal of Psychiatry 2000;157(8):1243-51.
90. Kennard BD, Emslie GJ, Mayes TL, Hughes JL. Relapse and recurrence in paediatric depression. Child and Adolescent Psychiatric Clinics of North America 2006;15:1057-79.
91. Kennedy N, Abbott R, Paykel ES. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. Psychological Medicine 2003;33:827-38.
92. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994-1999. British Journal of Psychiatry 2004;185:372-7.
93. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey replication. Archives of General Psychiatry 2005;62:593-602.
94. Kroll L, Harrington R, Jayson D. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. Journal of the American Academy of Child & Adolescent Psychiatry 1996;35(9):1156-61.
95. Lau MA, Segal ZV, Williams JM. Teasdale's differential activation hypothesis: implications for mechanisms of depressive relapse and suicidal behaviour. Behavior Research and Therapy 2004;42(9):1001-17.
96. Lewinsohn PM, Allen NB, Seeley JR, Gotlib IH. First onset versus recurrence of depression: differential processes of psychosocial risk. Journal of Abnormal Psychology 1999;108:483-9.
97. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. Journal of Consulting and Clinical Psychology 2004;72(1):31-40.
98. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al (Treatment for Adolescents with Depression Team). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292(7):807-20.
99. Marlatt GA, Gordon JR. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviours. New York: Guildford, 1985.
100. Martell CR, Dimidjian S, Herman-Dunn R. Behavioral Activation for Depression: A Clinician's Guide. New York: Guilford, 2010.
101. McDermott B, Baigent M, Chanen A, Fraser L, Graetz B, Hayman N et al. beyondblue Expert Working Committee. Clinical practice guidelines: depression in adolescents and young adults. beyondblue: the National Depression Initiative: Melbourne 2010.
102. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry 2006;40:616-22.
103. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit EA. Comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. Journal of the American Academy of Child & Adolescent Psychiatry 2006;45:1151-61.
104. Merry SN, Hetrick SE, Cox GR, Brudevold-Iversen T, Bir JJ, McDowell H. Psychological and educational interventions for preventing depression in children and adolescents. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003380.pub3]
105. National Institute for Health and Clinical Excellence (NICE). Depression in children and young people: identification and management in primary, community and secondary care. The British Psychological Society: Leicester, UK 2005.
106. Nobile M, Cataldo GM, Marino C, Molteni M. Diagnosis and treatment of dysthymia in children and adolescents. CNS Drugs 2003;17(13):927-46.
107. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs?. CNS Drugs 2001;15(12):941-54.
108. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. American Journal of Psychiatry 1992;149(8):999-1010.
109. Poznanski EO, Mokros HB. Children's Depressions Rating Scale, Revised (CDRS-R) Manual. Los Angeles: Western Psychological Services, 1996.
110. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. Journal of Clinical Psychopharmacology 2004;65(1):44-9.
111. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
112. Reynolds WM. Suicidal Ideation Questionnaire-Junior. Odessa, FL: Psychological Assessment Resources, 1987.
113. Rush AJ, Koran LM, Keller MB, et al.The treatment of chronicdepression, part 1: study design and rationale for evaluating thecomparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Journal of Clinical Psychiatry 1998;59:589-97.
114. Rutter M, Smith DJ. Psychosocial Disorders in Young People: Time Trends and Their Causes. Chichester, England: John Wiley & Sons, 1995.
115. Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, et al.Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Archives of General Psychiatry 2010;67(12):1256-64.
116. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al.A children's global assessment scale (CGAS). Archive of General Psychiatry 1983;40(11):1228-31.
117. Simon JS, Aguiar LM, Kunz NR, Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. Journal of Psychiatric Research 2004;38(3):249-57.
118. Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology 2000;68(4):615-23.
119. Thompson KN, Conus PO, Ward JL, Phillips LJ, Koutsogiannis J, Leicester S, et al.The initial prodrome to bipolar affective disorder: prospective case studies. Journal of Affective Disorders 2003;77(1):79-85.
120. Vallis MT, Shaw, BF, Dobson KS. The Cognitive Therapy Scale: Psychometric properties. Journal of Consulting and Clinical Psychology 1986;54(3):381-85.
121. van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A, et al.Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. Journal of Affective Disorders 1987;13:1-8.
122. Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects. Journal of Consulting and Clinical Psychology 2007;75(3):475-88.
123. Watanabe N, Hunot V, Omori IM, Churchill R, Furukawa TA. Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatrica Scandinavica 2007;116:84-95.
124. Weissman MM, Markowitz JC, Klerman GL. Clinician's Quick Guide to Interpersonal Psychotherapy. New York: Oxford University Press, 2007.
125. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychological Bulletin 2006;132:132-49.
126. World Health Organization. International Classification of Diseases and Related Health Problems 10th Revision (ICD-10) (accessible online: http://apps.who.int/classifications/apps/icd/icd10online/). Geneva: WHO, 2007.
127. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al.Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophrenia Research 2003;60(1):21-32.